Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03719586 · ClinicalTrials.gov registry record · Phase 2
Investigational Therapeutics for the Treatment of People With Ebola Virus Disease
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 681
- Enrollment target
NCT03719586: Completed Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT03719586 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 681 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (412% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03719586, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 681 participants
- Enrollment target
Study Summary
Background: Ebola virus can cause serious illness or death. No medicines are approved to treat it. Researchers need to test new medicines to see if they help people recover from Ebola and are safe to give. They need to test the drugs and compare them in a controlled way. Researchers want to test 4 drugs with people who have Ebola and are in treatment centers. Objective: To study the safety and effectiveness of 4 drugs for people with Ebola virus. Eligibility: People of any age with Ebola infection who are in treatment centers Design: Participants will be screened with questions, medical history, and blood tests. Participants will be randomly assigned to get 1 of 3 study drugs: * ZMapp by IV over about 4 hours. It will be given 3 times, 3 days apart. * Remdesivir by IV over about 1 hour. It will be given once a day for 10 days. * Mab114 by IV for 30-60 minutes. It will be given 1 time. * REGN-EB3 by IV for about 2 hours. It will be given 1 time. For at least a week, participants will stay in isolation in a clinic. They will: * Get supportive care and be monitored * Have a small plastic tube (IV) put in an arm vein for several days to give fluids and collect blood. * Get their study drug. * Be monitored for disease signs and drug side effects. They may get medicines for side effects. * Have blood and urine tests. Participants will stay in the clinic until they finish the study drug and are well enough to leave. Participants will have 2 follow-up visits over 2 months. They will answer questions and give blood and semen samples. ...
Primary Outcome
Number of Participants with Mortality by Day 28
Interventions
- DRUG Remdesivir
- DRUG ZMapp
- DRUG MAb114
- DRUG REGN-EB3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 681 participants |
| Start Date | 2018-11-21 |
| Est. Completion | 2020-08-18 |
| Phase | Phase 2 |
What the finished NCT03719586 record still lists
NCT03719586 is an interventional study that assigns participants to a tested intervention. The registered 681 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (412% higher).
The record links to 0 conditions, and to 4 interventions - of which Remdesivir is the first listed.
NCT03719586 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03719586 about?
NCT03719586 is a clinical study titled "Investigational Therapeutics for the Treatment of People With Ebola Virus Disease". Background: Ebola virus can cause serious illness or death. No medicines are approved to treat it. Researchers need to test new medicines to see if they help people recover from Ebola and are safe to give. They need to test the drugs and compare them in a controlled way. Researchers want to test 4 ...
What is the current status of trial NCT03719586?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 681 participants. The study started on 2018-11-21. Estimated completion is 2020-08-18.
What interventions are being tested in trial NCT03719586?
The interventions under investigation include: Remdesivir (DRUG), ZMapp (DRUG), MAb114 (DRUG), REGN-EB3 (DRUG).
Who is sponsoring clinical trial NCT03719586?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03719586's enrollment target sits among peer trials
681 48th of 2000 higher than 1,953 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05382559 · 681 participants · Phase 1
A Study of ASP3082 in Adults With Advanced Solid Tumors
- NCT03501706 · 680 participants · NA
An Assessment of Cognitive Improvement Training Among Mid-life Individuals
- NCT05626452 · 680 participants · NA
PrEP Optimization Among Women to Enhance Retention and Uptake
- NCT05753748 · 680 participants · NA
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI